TigaTx is focused on harnessing the unique capabilities of neutrophils, a type of white blood cell, to combat cancer through the development of engineered Immunoglobulin A (IgA). This innovative approach aims to create first-in-class therapies that engage neutrophils to target and eliminate tumor cells effectively. By leveraging the natural tumor-killing properties of neutrophils, TigaTx is pioneering a differentiated strategy in cancer treatment, which could potentially lead to more effective and targeted therapies.

The company is supported by a team of experienced drug developers and a robust scientific advisory board, ensuring a strong foundation for its research and development efforts. TigaTx's commitment to advancing its pipeline of products reflects its dedication to transforming cancer care through cutting-edge science and technology. With backing from accomplished investors, the company is well-positioned to make significant strides in the field of immuno-oncology.

United States

Unleashing the Tumor-Killing Power of Neutrophils with Engineered IgA
​We are pioneering first-in-class, engineered IgA as neutrophil engagers to fight cancer. 

TigaTx

Company Details